Pfizer (NYSE:PFE) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

04 Nov 2026, 17:10 by Mitch Edgeman · The Markets Daily

Pfizer (NYSE:PFE – Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.74 by $0.13, Zacks reports. The company had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.87 EPS.

Here are the key takeaways from Pfizer’s conference call:

Pfizer raised its 2026 guidance, increasing revenue expectations to $62 billion–$64 billion and adjusted diluted EPS to $2.95–$3.05, supported by strong year-to-date execution.
Non-COVID products grew 7% operationally, while launched and acquired products increased 32%, led by PADCEV, NURTEC, and LORBRENA. Pfizer said it remains on track to deliver nearly all of its planned $7.2 billion in net savings by the end of 2026 and expects an additional $2.5 billion in savings from 2027–2029.
Management highlighted encouraging pipeline progress, including positive phase III data for ELREXFIO, promising results for atirmociclib and tivunatamig, and continued development of obesity treatments berobenatide and amylin combinations. Pfizer expects multiple regulatory decisions, readouts, and pivotal study starts over the next 12 months.
Pfizer continues to face a significant loss-of-exclusivity transition, including upcoming pressure from IBRANCE and XTANDI in the U.S. and ELIQUIS internationally. COVID-19 products and the PREVNAR family declined in the quarter, while 2027 results will also reflect IRA, 340B, MFN, and pricing impacts.

Pfizer Price Performance

Shares of PFE stock traded up $0.56 during trading on Wednesday, hitting $30.55. The company had a trading volume of 19,564,596 shares, compared to its average volume of 39,685,324. Pfizer has a 52 week low of $23.62 and a 52 week high of $31.06. The stock has a market capitalization of $174.15 billion, a price-to-earnings ratio of 40.20, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock’s 50-day moving average is $28.64 and its two-hundred day moving average is $26.84.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is currently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and adjusted EPS guidance to $2.95–$3.05, following third-quarter results that topped analyst estimates. Pfizer Q3 earnings highlights
Positive Sentiment: Growth beyond COVID is helping support the outlook: launched and acquired products grew 32% operationally in Q3, while non-COVID products overall grew 7%. Eliquis and oncology medicines were among the growth drivers. Pfizer: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: Investors also have potential longer-term upside to watch in Pfizer’s renewed obesity-drug push, which CEO Albert Bourla says could draw on the company’s experience building successful medicines. The opportunity is not yet established commercial growth. Pfizer CEO Bourla on obesity market
Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan as permanent CFO. The appointment provides leadership continuity, but no immediate financial impact was reported. Pfizer appoints Cecile Guegan as CFO
Negative Sentiment: Q3 revenue was essentially flat year over year, as falling COVID vaccine and treatment sales—including declines in Comirnaty and Paxlovid—offset growth elsewhere. This underscores Pfizer’s ongoing need to replace pandemic-era revenue. Pfizer Q3 revenue and product growth

Analyst Upgrades and Downgrades

A number of brokerages have commented on PFE. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Bank of America lowered their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. BMO Capital Markets cut their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Scotiabank upped their price objective on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Finally, HSBC increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.65.

Check Out Our Latest Stock Analysis on PFE

About Pfizer

(Get Free Report)

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.